secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001104659-25-086669
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon
--------------------------------------------------------------------------------

- $100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.
- Interest at three-month SOFR (3.75% floor) + 6.50%, payable quarterly; amortization begins Sept 2028.
- Proceeds to support U.S. commercialization of PAPZIMEOS and potential expansion into international and pediatric indications.
- Loan is senior secured by substantially all U.S. assets, including IP; customary covenants and events of default.
- CFO states strengthening balance sheet provides financial flexibility as company enters projected significant growth period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000110465925086669/0001104659-25-086669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000110465925086669/tm2524946d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-086669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer